FIELD: medicine.
SUBSTANCE: invention relates to medicine and concerns a tetradecapeptide of general formula H-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-X-Gly-Pro-Y, where X=Leu, Y=-βpAla-His-OH (II); X=Nle, Y=-His-Arg-OH (III).
EFFECT: invention provides an improvement in the recovery of heart function and a reduction in irreversible damages to cardiomyocytes after an ischemia reperfusion injury.
1 cl, 1 dwg, 4 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CRYSTALLOID CARDIOPLEGIC SOLUTIONS, CONTAINING DODECAPEPTIDES (VERSIONS) | 2013 |
|
RU2549470C1 |
| DODECAPEPTIDES HAVING CARDIOPROTECTIVE PROPERTIES | 2010 |
|
RU2457216C1 |
| MEANS INCREASING HEART RESISTANCE TO REPERFUSION DAMAGE | 2016 |
|
RU2642826C1 |
| WATER-SOLUBLE COMPOSITION, POSSESSIVE PROPERTIES OF CARDIO-PROTECTOR | 2010 |
|
RU2438698C1 |
| METHOD FOR EVALUATING THE STATE OF MYOCARDIUM IN CARDIOSURGICAL INTERVENTIONS UNDER CONDITIONS OF CARDIOPLEGIC PROTECTION | 2017 |
|
RU2651364C1 |
| AGENT IMPROVING CARDIAC RESISTANCE TO ISCHEMIC AND FOLLOWING REPERFUSION INJURIES | 2012 |
|
RU2488404C1 |
| PEPTIDE COMPOUND RECOVERING FUNCTION OF MYOCARDIUM | 2004 |
|
RU2255756C1 |
| APOPTOSIS INHIBITORS AND USE THEREOF | 2011 |
|
RU2582247C2 |
| THERAPEUTIC DOSING OF NEUREGULIN OR ITS SUB-SEQUENCE FOR TREATING OR PREVENTING HEART FAILURE | 2019 |
|
RU2719199C1 |
| THERAPEUTIC AGENT FOR THE TREATMENT OF CARDIOMYOPATHY, PREVIOUS MYOCARDIAL INFARCTION AND CHRONIC HEART FAILURE | 2018 |
|
RU2795320C2 |
